Cited by 2,217CAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Open access

Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A., Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N., Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J., Rezvani, Katayoun·2020·New England Journal of Medicine

DOI 10.1056/nejmoa1910607PMC PMC7101242

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1910607

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citation
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citation
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 301–400 of 1,000

Bi-order multimodal integration of single-cell data
Dou, J., Liang, S., Mohanty, V., Miao, Q., Huang, Y., Liang, Q., Cheng, X., Kim, S., Choi, J., Li, Y., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02679-x · Cited by 66
Self-citation
The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment
Huang, X., Zhang, F., Wang, X., & Liu, K. (2022) · Cancers · doi:10.3390/cancers14112756 · Cited by 69
Chimeric Antigen Receptor beyond CAR-T Cells
Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 65
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 68
Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion
Allan, D., Chakraborty, M., Waller, G., Hochman, M. J., Poolcharoen, A., Reger, R. N., & Childs, R. W. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.008 · Cited by 65
Recent advances in biomaterial-boosted adoptive cell therapy
Xue, Y., Che, J., Ji, X., Li, Y., Xie, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00786f · Cited by 70
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin, E., Bak, S. H., Park, T., Kim, J.-W., Yoon, S. R., Jung, H., & Noh, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192907 · Cited by 71
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia, A., Tarannum, M., Lérias, J. R., Piccinelli, S., Borrego, L. M., Maeurer, M. J., Romee, R., & Castillo-Martín, M. (2024) · Cells · doi:10.3390/cells13050451 · Cited by 69
Natural Born Killers: NK Cells in Cancer Therapy
Franks, S. E., Wolfson, B., & Hodge, J. W. (2020) · Cancers · doi:10.3390/cancers12082131 · Cited by 68
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 68
CAR T-Cell Production Using Nonviral Approaches
Lukjanov, V., Koutná, I., & Šimara, P. (2021) · Journal of Immunology Research · doi:10.1155/2021/6644685 · Cited by 68
Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy
Choi, C., & Finlay, D. K. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02377-8 · Cited by 66
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Ebrahimiyan, H., Tamimi, A., Shokoohian, B., Minaei, N., Memarnejadian, A., Hossein‐Khannazer, N., Hassan, M., & Vosough, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108587 · Cited by 64
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
Golubovskaya, V., Sienkiewicz, J., Sun, J., Zhang, S., Huang, Y., Zhou, H., Harto, H., Xu, S., Berahovich, R., & Wu, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713364 · Cited by 67
Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
Silvestre, R. N., Eitler, J., de Azevedo, J. T. C., Tirapelle, M. C., Fantacini, D. M. C., de Souza, L. E. B., Swiech, K., Covas, D. T., Calado, R. T., Montero, P. O., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226518 · Cited by 64
Five decades of natural killer cell discovery
Lanier, L. L. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20231222 · Cited by 54
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Acharya, S., Başar, R., Daher, M., Rafei, H., Li, P., Uprety, N., Ensley, E. L., Shanley, M., Kumar, B., Banerjee, P. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0096 · Cited by 69
Self-citation
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Unterrainer, M., Ruzicka, M., Fabritius, M. P., Mittlmeier, L. M., Winkelmann, M., Rübenthaler, J., Brendel, M., Subklewe, M. S., von Bergwelt‐Baildon, M., Ricke, J., et al. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00190-1 · Cited by 65
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
Charap, A., Enokida, T., Brody, R., Sfakianos, J. P., Miles, B. A., Bhardwaj, N., & Horowitz, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001523 · Cited by 66
Synapse-tuned CARs enhance immune cell anti-tumor activity
Chockley, P. J., Ibañez-Vega, J., Krenciute, G., Talbot, L. J., & Gottschalk, S. M. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01650-2 · Cited by 69
CAR-T cell therapy: Where are we now, and where are we heading?
Wang, J., & Wang, L. (2023) · Blood Science · doi:10.1097/bs9.0000000000000173 · Cited by 64
Emerging trends in clinical allogeneic CAR cell therapy
Li, Y.-R., Zhu, Y., Fang, Y., Lyu, Z., & Yang, L. (2025) · Med · doi:10.1016/j.medj.2025.100677 · Cited by 72
Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities
Kansagra, A. J., Farnia, S. H., & Majhail, N. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279151 · Cited by 62
Transcriptional Regulation of Natural Killer Cell Development and Functions
Wang, D., & Malarkannan, S. (2020) · Cancers · doi:10.3390/cancers12061591 · Cited by 65
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells
Liu, E., Ang, S., Kerbauy, L. N., Başar, R., Kaur, I., Kaplan, M., Li, L., Tong, Y., Daher, M., Ensley, E. L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626098 · Cited by 66
Self-citation
Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity
Mikelez-Alonso, I., Magadán, S., González‐Fernández, Á., & Borrego, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113860 · Cited by 63
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Kilgour, M. K., Bastin, D. J., Lee, S., Ardolino, M., McComb, S., & Visram, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166038 · Cited by 66
The Black Hole: CAR T Cell Therapy in AML
Atilla, E., & Benabdellah, K. (2023) · Cancers · doi:10.3390/cancers15102713 · Cited by 68
T-BET and EOMES sustain mature human NK cell identity and antitumor function
Wong, P., Foltz, J. A., Chang, L., Neal, C. C., Yao, T., Cubitt, C. C., Tran, J., Kersting-Schadek, S., Palakurty, S., Jaeger, N., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162530 · Cited by 68
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells
Rafei, H., Başar, R., Acharya, S., Hsu, Y.-S., Liu, P., Zhang, D., Bohn, T., Liang, Q., Mohanty, V., Upadhyay, R., et al. (2025) · Nature · doi:10.1038/s41586-025-09087-8 · Cited by 69
Self-citation
Prospects and challenges for use of CAR T cell therapies in solid tumors
Ramakrishna, S., Barsan, V. V., & Mackall, C. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738378 · Cited by 62
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Ragoonanan, D. S., Khazal, S. J., Abdel‐Azim, H., McCall, D. C., Cuglievan, B., Tambaro, F. P., Ahmad, A. H., Rowan, C. M., Gutiérrez, C., Schadler, K., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00474-4 · Cited by 62
Self-citation
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
Shaver, K. A., Croom-Perez, T. J., & Copik, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679117 · Cited by 68
Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
Phung, S. K., Miller, J. S., & Felices, M. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00550-6 · Cited by 64
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
Bachiller, M., Pérez-Amill, L., Battram, A. M., Carné, S. C., Najjar, A. M., Verhoeyen, E., Juan, M., Urbano-Ispizúa, Á., & Martín-Antonio, B. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002866 · Cited by 61
Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications
Si, C., Gao, J., & Ma, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02045-4 · Cited by 65
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade
Bozward, A. G., Warricker, F., Oo, Y. H., & Khakoo, S. I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643310 · Cited by 65
CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 63
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
Zhou, Y., Li, M., Zhou, K., Brown, J., Tsao, T., Cen, X., Husman, T., Bajpai, A., Dunn, Z. S., & Yang, L. (2022) · Cancers · doi:10.3390/cancers14092266 · Cited by 61
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
Strecker, M. I., Wlotzka, K., Straßheimer, F., Roller, B., Ludmirski, G., König, S., Röder, J., Opitz, C., Alekseeva, T., Reul, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2127508 · Cited by 60
Adaptive NK cell response to human cytomegalovirus: Facts and open issues
López‐Botet, M., Maria, A. D., Muntasell, A., Chiesa, M. D., & Vilches, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101706 · Cited by 65
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments
Kennedy, P. R., Arvindam, U. S., Phung, S. K., Ettestad, B., Feng, X., Li, Y., Kile, Q. M., Hinderlie, P., Khaw, M. J., Huang, R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn1849 · Cited by 62
Managing allorejection in off-the-shelf CAR-engineered cell therapies
Li, Y.-R., Fang, Y., Niu, S., Chen, Y., Lyu, Z., & Yang, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.035 · Cited by 65
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
Li, Y.-R., Fang, Y., Niu, S., Zhu, Y., Chen, Y., Lyu, Z., Zhu, E., Tian, Y., Huang, J., Rezek, V. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56270-6 · Cited by 62
High-Throughput 3D In Vitro Tumor Vasculature Model for Real-Time Monitoring of Immune Cell Infiltration and Cytotoxicity
Song, J., Choi, H., Koh, S. K., Park, D., Yu, J., Kang, H., Kim, Y., Cho, D., & Jeon, N. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733317 · Cited by 60
Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report
Zhang, X., Guo, Y., Ji, Y., Gao, Y., Zhang, M., Liu, Y., Zhu, W., & Lu, P. (2022) · Cell Transplantation · doi:10.1177/09636897221094244 · Cited by 59
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Hematology · doi:10.1182/hematology.2020002547 · Cited by 57
Self-citation
Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV
Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Sezgin, Y., Devine, R. D., Lyberger, J. M., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100236 · Cited by 59
Macrophage immunotherapy: overcoming impediments to realize promise
Sly, L. M., & McKay, D. M. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.10.002 · Cited by 59
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Wang, X., Yang, X., Yuan, X., Wang, W., & Wang, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00341-7 · Cited by 60
Engineering innate immune cells for cancer immunotherapy
Tarannum, M., Ding, X., Barisa, M., Hu, S., Anderson, J., Romee, R., & Zhang, J. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02629-5 · Cited by 64
Chimeric antigen receptor T‐cell therapies: Optimising the dose
Dasyam, N., George, P., & Weinkove, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14281 · Cited by 58
Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment
Lee, Y. E., Ju, A., Choi, H. W., Kim, J., Kim, E. E., Kim, T. S., Kang, H. J., Kim, S.-Y., Jang, J., Ku, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.016 · Cited by 59
TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Poorebrahim, M., Mohammadkhani, N., Mahmoudi, R., Gholizadeh, M., Fakhr, E., & Arregui, A. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00307-7 · Cited by 61
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
Baysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 58
Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
Tarannum, M., Romee, R., & Shapiro, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859177 · Cited by 59
Advances in NK cell therapy for brain tumors
Fares, J., Davis, Z., Rechberger, J. S., Toll, S. A., Schwartz, J., Daniels, D. J., Miller, J. S., & Khatua, S. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00356-1 · Cited by 67
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Zhang, Y., Zhou, W., Yang, J., Yang, J., & Wang, W. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00431-0 · Cited by 58
Immunoengineering can overcome the glycocalyx armour of cancer cells
Park, S., Colville, M. J., Paek, J. H., Shurer, C. R., Singh, A. L., Secor, E. J., Sailer, C. J., Huang, L., Kuo, J. C., Goudge, M. C., et al. (2024) · Nature Materials · doi:10.1038/s41563-024-01808-0 · Cited by 58
CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
Li, H., Yang, C., Cheng, H., Huang, S., & Zheng, Y. (2021) · Journal of Cancer · doi:10.7150/jca.50509 · Cited by 59
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy
Cortés‐Selva, D., Dasgupta, B., Singh, S., & Grewal, I. S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.004 · Cited by 61
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success
Fiorenza, S., & Turtle, C. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00477-8 · Cited by 60
Biomimetic nanotherapy: core–shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma
Zhao, Q., Jiang, D., Sun, X., Mo, Q., Chen, S., Chen, W., Gui, R., & Ma, X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00922-4 · Cited by 56
Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice
Ghasemzadeh, M., Ghasemzadeh, A., & Hosseini, E. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.09.004 · Cited by 55
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi, H., Chrobok, M., Meinke, S., Gran, C., Marquardt, N., Afram, G., Sütlü, T., Gilljam, M., Stellan, B., Wagner, A. K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100508 · Cited by 55
The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells
Moscarelli, J. R., Zahavi, D. J., Maynard, R. E., & Weiner, L. M. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.025 · Cited by 59
Current Progress of CAR-NK Therapy in Cancer Treatment
Pang, Z., Wang, Z., Li, F., Feng, C., & Mu, X. N. (2022) · Cancers · doi:10.3390/cancers14174318 · Cited by 60
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Ghaedrahmati, F., Esmaeil, N., & Abbaspour, M. (2022) · 癌症：英文版 · doi:10.1002/cac2.12394 · Cited by 57
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer
Lyu, Z., Niu, S., Fang, Y., Chen, Y., Li, Y.-R., & Yang, L. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00654-3 · Cited by 61
Engineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 62
Self-citation
Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor
Gong, Y., Wolterink, R. G. J. K., Janssen, I., Groot, A. J., Bos, G. M. J., & Germeraad, W. T. V. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.017 · Cited by 57
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Robbins, Y. L., Greene, S., Friedman, J., Clavijo, P. E., Waes, C. V., Fabian, K. P., Padget, M. R., Sater, H. A., Lee, J. H., Soon‐Shiong, P., et al. (2020) · eLife · doi:10.7554/elife.54854 · Cited by 57
The potential of CAR T cell therapy for prostate cancer
Wolf, P., Alzubi, J., Gratzke, C., & Cathomen, T. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00488-8 · Cited by 58
IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors
Hombach, A. A., Barden, M., Hannappel, L., Chmielewski, M. M., Rappl, G., Sachinidis, A., & Abken, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.011 · Cited by 56
Biology and Treatment of Richter Transformation
Condoluci, A., & Rossi, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.829983 · Cited by 55
Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
Ren, X., Peng, M., Peng, X., Yao, W., Galbo, P. M., Corrigan, D. T., Wang, H., Su, Y., Dong, X., Sun, Q., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163620 · Cited by 59
CAR-NK cells for cancer immunotherapy: recent advances and future directions
Li, T., Niu, M., Zhang, W., Qin, S., Zhou, J., & Yi, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1361194 · Cited by 61
Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools
Dewaker, V., Morya, V. K., Kim, Y. H., Park, S. T., Kim, H. S., & Koh, Y. H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00764-4 · Cited by 62
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
Alfarra, H., Weir, J. A., Grieve, S., & Reiman, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575609 · Cited by 57
Engineering CAR T Cells to Target the HIV Reservoir
Mu, W., Carrillo, M. A., & Kitchen, S. G. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00410 · Cited by 55
HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-the-Shelf” Immunotherapy
Hoerster, K., Uhrberg, M., Wiek, C., Horn, P. A., Hanenberg, H., & Heinrichs, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586168 · Cited by 59
Hematopoietic Stem Cell- and Induced Pluripotent Stem Cell-Derived CAR-NK Cells as Reliable Cell-Based Therapy Solutions
Arias, J., Yu, J., Varshney, M., Inzunza, J., & Nalvarte, I. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0459 · Cited by 56
Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer
Luo, X., Xu, J., Yu, J., & Yi, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692360 · Cited by 58
Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy
Zhang, W., Zhao, Z., & Li, F. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.02.015 · Cited by 57
Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
Lu, T., Ma, R., Dong, W., Teng, K., Kollath, D. S., Li, Z., Yi, J., Bustillos, C. G., Ma, S., Tian, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30216-8 · Cited by 59
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms
Zhou, X., Wang, Y., Dou, Z., Delfanti, G., Tsahouridis, O., Pellegry, C. M., Zingarelli, M., Atassi, G., Woodcock, M. G., Casorati, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00830-0 · Cited by 59
Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer
Zhao, X., Cai, L., Hu, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584099 · Cited by 62
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
Ma, M. T., Badeti, S., Chen, C.-H., Kim, J., Choudhary, A. K., Honnen, B., Reichman, C., Calianese, D. C., Pinter, A., Jiang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652223 · Cited by 54
CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer
Włodarczyk, M., & Pyrzyńska, B. (2022) · Cancers · doi:10.3390/cancers15010117 · Cited by 54
Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration
Li, Z., Zhang, S., Fu, Z., Liu, Y., Man, Z., Shi, C., Tang, C., Chen, C., Chai, Q., Yang, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3365 · Cited by 54
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
Bexte, T., Botezatu, L., Miskey, C., Gierschek, F., Moter, A., Wendel, P., Reindl, L. M., Campe, J., Villena-Ossa, J. F., Gebel, V., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.022 · Cited by 54
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation
Luo, J., Guo, M., Huang, M., Liu, Y., Qian, Y., Liu, Q., & Cao, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02158-2 · Cited by 55
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression
Rea, A., Santana-Hernández, S., Villanueva, J., Sanvicente-García, M., Cabo, M., Suárez-Olmos, J., Quimis, F. G., Qin, M., Llorens, E., Blasco-Benito, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02103-z · Cited by 57
Target tumor microenvironment by innate T cells
Li, Y.-R., Wilson, M., & Yang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999549 · Cited by 56
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
Wu, X., & Matosevic, S. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.011 · Cited by 53
Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology
Youssef, E. M., Fletcher, B., & Palmer, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1527600 · Cited by 63
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Biederstädt, A., Başar, R., Park, J.-M., Uprety, N., Shrestha, R., Silva, F. R., Dede, M., Watts, J., Acharya, S., Xiong, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.021 · Cited by 56
Self-citation
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
Gao, J., Li, M., Sun, M., Yu, Y., Kong, R., Xu, X., Liu, S., Chen, Q., Li, X., Wu, Y., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01671-x · Cited by 53
Concise review on optimized methods in production and transduction of lentiviral vectors in order to facilitate immunotherapy and gene therapy
Ghaleh, H. E. G., Bolandian, M., Dorostkar, R., Jafari, A., & Pour, M. F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110276 · Cited by 55
Drug target validation in primary human natural killer cells using CRISPR RNP
Rautela, J., Surgenor, E. E., & Huntington, N. D. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2ma0620-074r · Cited by 74

Authors: Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Nunez Cortes, A., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Stem Cell Transplantation and Cellular Therapy (E.L., D.M., P.B., R.B., L.N.K., B.O., M. Kaplan, V.N., I.K., A.N.C., M.D., C.H., P.K., R.M., Y.N., R.C., E.J.S., K.R.), Nuclear Medicine (H.A.M.), Leukemia (P. Thompson, W.W., M. Keating), Biostatistics (P. Thall), Laboratory Medicine (K.C.), Hematopathology (E.N.C.), and Lymphoma and Myeloma (S.N., M.W.), University of Texas M.D. Anderson Cancer Center, Houston.
ORCID: Liu, Enli
Banerjee, Pinaki
Macapinlac, Homer A.
Thompson, Philip
Thall, Peter
Kaplan, Mecit
Cao, Kai
Daher, May
Hosing, Chitra
Cohen, Evan N.
Kebriaei, Partow
Mehta, Rohtesh
Neelapu, Sattva
Nieto, Yago
Wang, Michael
Wierda, William
Keating, Michael
Champlin, Richard
Shpall, Elizabeth J.
Rezvani, Katayoun
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-02-06
Volume: 382
Issue: 6
Pages: 545-553
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1910607
PMC: PMC7101242
OpenAlex: W3004611567
Cited by: 2,217
References: 37
Citations by year: 2026: 282 · 2025: 337 · 2024: 332 · 2023: 323 · 2022: 353 · 2021: 379 · 2020: 205
FWCI: 113.83
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: M.D. Anderson Cancer Center CLL and lymphoma Moonshot Grants
National Institutes of Health (1 R01 CA211044-01, 5P01CA148600-03, CA016672, P50CA100632-16)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CAR-NK cells, chimeric antigen receptor, natural killer cells, anti-CD19, relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia, Richter transformation, lymphodepleting chemotherapy, cytokine release syndrome, neurotoxicity, graft-versus-host disease, interleukin-6, CAR T-cell toxicity
MeSH terms: Receptors, Chimeric Antigen, Aged, Female, Fetal Blood, Genetic Vectors, Humans, Killer Cells, Natural, Lymphoma, Non-Hodgkin, Male, Middle Aged, Remission Induction, Retroviridae, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transplantation Conditioning, Allografts, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks